@article{StoppePatelZarbocketal.2023, author = {Stoppe, Christian and Patel, Jayshil J. and Zarbock, Alex and Lee, Zheng-Yii and Rice, Todd W. and Mafrici, Bruno and Wehner, Rebecca and Chan, Man Hung Manuel and Lai, Peter Chi Keung and MacEachern, Kristen and Myrianthefs, Pavlos and Tsigou, Evdoxia and Ortiz-Reyes, Luis and Jiang, Xuran and Day, Andrew G. and Hasan, M. Shahnaz and Meybohm, Patrick and Ke, Lu and Heyland, Daren K.}, title = {The impact of higher protein dosing on outcomes in critically ill patients with acute kidney injury: a post hoc analysis of the EFFORT protein trial}, series = {Critical Care}, volume = {27}, journal = {Critical Care}, doi = {10.1186/s13054-023-04663-8}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-357221}, year = {2023}, abstract = {Background Based on low-quality evidence, current nutrition guidelines recommend the delivery of high-dose protein in critically ill patients. The EFFORT Protein trial showed that higher protein dose is not associated with improved outcomes, whereas the effects in critically ill patients who developed acute kidney injury (AKI) need further evaluation. The overall aim is to evaluate the effects of high-dose protein in critically ill patients who developed different stages of AKI. Methods In this post hoc analysis of the EFFORT Protein trial, we investigated the effect of high versus usual protein dose (≥ 2.2 vs. ≤ 1.2 g/kg body weight/day) on time-to-discharge alive from the hospital (TTDA) and 60-day mortality and in different subgroups in critically ill patients with AKI as defined by the Kidney Disease Improving Global Outcomes (KDIGO) criteria within 7 days of ICU admission. The associations of protein dose with incidence and duration of kidney replacement therapy (KRT) were also investigated. Results Of the 1329 randomized patients, 312 developed AKI and were included in this analysis (163 in the high and 149 in the usual protein dose group). High protein was associated with a slower time-to-discharge alive from the hospital (TTDA) (hazard ratio 0.5, 95\% CI 0.4-0.8) and higher 60-day mortality (relative risk 1.4 (95\% CI 1.1-1.8). Effect modification was not statistically significant for any subgroup, and no subgroups suggested a beneficial effect of higher protein, although the harmful effect of higher protein target appeared to disappear in patients who received kidney replacement therapy (KRT). Protein dose was not significantly associated with the incidence of AKI and KRT or duration of KRT. Conclusions In critically ill patients with AKI, high protein may be associated with worse outcomes in all AKI stages. Recommendation of higher protein dosing in AKI patients should be carefully re-evaluated to avoid potential harmful effects especially in patients who were not treated with KRT. Trial registration: This study is registered at ClinicalTrials.gov (NCT03160547) on May 17th 2017.}, language = {en} } @article{JockelSchneiderSchlagenhaufPetsosetal.2021, author = {Jockel-Schneider, Yvonne and Schlagenhauf, Ulrich and Petsos, Hari and R{\"u}ttermann, Stefan and Schmidt, Jana and Ziebolz, Dirk and Wehner, Christian and Laky, Markus and Rott, Thea and Noack, Michael and Noack, Barbara and Lorenz, Katrin}, title = {Impact of 0.1\% octenidine mouthwash on plaque re-growth in healthy adults: a multi-center phase 3 randomized clinical trial}, series = {Clinical Oral Investigations}, volume = {25}, journal = {Clinical Oral Investigations}, number = {7}, issn = {1432-6981}, doi = {10.1007/s00784-021-03781-3}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-307629}, pages = {4681-4689}, year = {2021}, abstract = {Objectives To investigate plaque inhibition of 0.1\% octenidine mouthwash (OCT) vs. placebo over 5 days in the absence of mechanical plaque control. Materials and methods For this randomized, placebo-controlled, double-blind, parallel group, multi-center phase 3 study, 201 healthy adults were recruited. After baseline recording of plaque index (PI) and gingival index (GI), collection of salivary samples, and dental prophylaxis, subjects were randomly assigned to OCT or placebo mouthwash in a 3:1 ratio. Rinsing was performed twice daily for 30 s. Colony forming units in saliva were determined before and after the first rinse. At day 5, PI, GI, and tooth discoloration index (DI) were assessed. Non-parametric van Elteren tests were applied with a significance level of p < 0.05. Results Treatment with OCT inhibited plaque formation more than treatment with placebo (PI: 0.36 vs. 1.29; p < 0.0001). OCT reduced GI (0.04 vs. placebo 0.00; p = 0.003) and salivary bacterial counts (2.73 vs. placebo 0.24 lgCFU/ml; p < 0.0001). Tooth discoloration was slightly higher under OCT (DI: 0.25 vs. placebo 0.00; p = 0.0011). Mild tongue staining and dysgeusia occurred. Conclusions OCT 0.1\% mouthwash inhibits plaque formation over 5 days. It therefore can be recommended when regular oral hygiene is temporarily compromised. Clinical relevance When individual plaque control is compromised, rinsing with octenidine mouthwash is recommended to maintain healthy oral conditions while side effects are limited.}, language = {en} } @article{FarmerStrzelczykFinisguerraetal.2021, author = {Farmer, Adam D. and Strzelczyk, Adam and Finisguerra, Alessandra and Gourine, Alexander V. and Gharabaghi, Alireza and Hasan, Alkomiet and Burger, Andreas M. and Jaramillo, Andr{\´e}s M. and Mertens, Ann and Majid, Arshad and Verkuil, Bart and Badran, Bashar W. and Ventura-Bort, Carlos and Gaul, Charly and Beste, Christian and Warren, Christopher M. and Quintana, Daniel S. and H{\"a}mmerer, Dorothea and Freri, Elena and Frangos, Eleni and Tobaldini, Eleonora and Kaniusas, Eugenijus and Rosenow, Felix and Capone, Fioravante and Panetsos, Fivos and Ackland, Gareth L. and Kaithwas, Gaurav and O'Leary, Georgia H. and Genheimer, Hannah and Jacobs, Heidi I. L. and Van Diest, Ilse and Schoenen, Jean and Redgrave, Jessica and Fang, Jiliang and Deuchars, Jim and Sz{\´e}les, Jozsef C. and Thayer, Julian F. and More, Kaushik and Vonck, Kristl and Steenbergen, Laura and Vianna, Lauro C. and McTeague, Lisa M. and Ludwig, Mareike and Veldhuizen, Maria G. and De Couck, Marijke and Casazza, Marina and Keute, Marius and Bikson, Marom and Andreatta, Marta and D'Agostini, Martina and Weymar, Mathias and Betts, Matthew and Prigge, Matthias and Kaess, Michael and Roden, Michael and Thai, Michelle and Schuster, Nathaniel M. and Montano, Nicola and Hansen, Niels and Kroemer, Nils B. and Rong, Peijing and Fischer, Rico and Howland, Robert H. and Sclocco, Roberta and Sellaro, Roberta and Garcia, Ronald G. and Bauer, Sebastian and Gancheva, Sofiya and Stavrakis, Stavros and Kampusch, Stefan and Deuchars, Susan A. and Wehner, Sven and Laborde, Sylvain and Usichenko, Taras and Polak, Thomas and Zaehle, Tino and Borges, Uirassu and Teckentrup, Vanessa and Jandackova, Vera K. and Napadow, Vitaly and Koenig, Julian}, title = {International Consensus Based Review and Recommendations for Minimum Reporting Standards in Research on Transcutaneous Vagus Nerve Stimulation (Version 2020)}, series = {Frontiers in Human Neuroscience}, volume = {14}, journal = {Frontiers in Human Neuroscience}, issn = {1662-5161}, doi = {10.3389/fnhum.2020.568051}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-234346}, year = {2021}, abstract = {Given its non-invasive nature, there is increasing interest in the use of transcutaneous vagus nerve stimulation (tVNS) across basic, translational and clinical research. Contemporaneously, tVNS can be achieved by stimulating either the auricular branch or the cervical bundle of the vagus nerve, referred to as transcutaneous auricular vagus nerve stimulation(VNS) and transcutaneous cervical VNS, respectively. In order to advance the field in a systematic manner, studies using these technologies need to adequately report sufficient methodological detail to enable comparison of results between studies, replication of studies, as well as enhancing study participant safety. We systematically reviewed the existing tVNS literature to evaluate current reporting practices. Based on this review, and consensus among participating authors, we propose a set of minimal reporting items to guide future tVNS studies. The suggested items address specific technical aspects of the device and stimulation parameters. We also cover general recommendations including inclusion and exclusion criteria for participants, outcome parameters and the detailed reporting of side effects. Furthermore, we review strategies used to identify the optimal stimulation parameters for a given research setting and summarize ongoing developments in animal research with potential implications for the application of tVNS in humans. Finally, we discuss the potential of tVNS in future research as well as the associated challenges across several disciplines in research and clinical practice.}, language = {en} } @article{ReulChristHarteltetal.2019, author = {Reul, Christian and Christ, Dennis and Hartelt, Alexander and Balbach, Nico and Wehner, Maximilian and Springmann, Uwe and Wick, Christoph and Grundig, Christine and B{\"u}ttner, Andreas and Puppe, Frank}, title = {OCR4all—An open-source tool providing a (semi-)automatic OCR workflow for historical printings}, series = {Applied Sciences}, volume = {9}, journal = {Applied Sciences}, number = {22}, issn = {2076-3417}, doi = {10.3390/app9224853}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-193103}, pages = {4853}, year = {2019}, abstract = {Optical Character Recognition (OCR) on historical printings is a challenging task mainly due to the complexity of the layout and the highly variant typography. Nevertheless, in the last few years, great progress has been made in the area of historical OCR, resulting in several powerful open-source tools for preprocessing, layout analysis and segmentation, character recognition, and post-processing. The drawback of these tools often is their limited applicability by non-technical users like humanist scholars and in particular the combined use of several tools in a workflow. In this paper, we present an open-source OCR software called OCR4all, which combines state-of-the-art OCR components and continuous model training into a comprehensive workflow. While a variety of materials can already be processed fully automatically, books with more complex layouts require manual intervention by the users. This is mostly due to the fact that the required ground truth for training stronger mixed models (for segmentation, as well as text recognition) is not available, yet, neither in the desired quantity nor quality. To deal with this issue in the short run, OCR4all offers a comfortable GUI that allows error corrections not only in the final output, but already in early stages to minimize error propagations. In the long run, this constant manual correction produces large quantities of valuable, high quality training material, which can be used to improve fully automatic approaches. Further on, extensive configuration capabilities are provided to set the degree of automation of the workflow and to make adaptations to the carefully selected default parameters for specific printings, if necessary. During experiments, the fully automated application on 19th Century novels showed that OCR4all can considerably outperform the commercial state-of-the-art tool ABBYY Finereader on moderate layouts if suitably pretrained mixed OCR models are available. Furthermore, on very complex early printed books, even users with minimal or no experience were able to capture the text with manageable effort and great quality, achieving excellent Character Error Rates (CERs) below 0.5\%. The architecture of OCR4all allows the easy integration (or substitution) of newly developed tools for its main components by standardized interfaces like PageXML, thus aiming at continual higher automation for historical printings.}, language = {en} }